

Supporting Information

for

A cancer-targeted drug delivery system developed with gold nanoparticles mediated DNA-doxorubicin conjugates

Yu Qing Du,^a Xiao Xi Yang,^a Wen Long Li,^b Jian Wang^{*,a} and Cheng Zhi Huang^{*,a}

^a *Key Laboratory of Luminescence and Real-Time Analytical Chemistry (southwest University),
Ministry of Education, College of Pharmaceutical Sciences , Southwest University, 400715
Chongqing, PR China.*

^b *College of Chemistry and Chemical Engineering, Southwest University, 400715 Chongqing, PR
China*

E-mail: wj123456@swu.edu.cn; chengzhi@swu.edu.cn




Fig. S1 Optimization of the reaction time between AuNPs-DNA(Dox) and PrPC. Concentrations, AuNPs-DNA(Dox), 2nM; PrPC, 200nM.




Fig. S2 The standard linear calibration curve of Dox. (λ_{ex} , 490nm; λ_{em} , 562nm)




Fig. S3 The stability of the AuNPs-DNA(Dox) complex. The fluorescence of 2 nM AuNP-MB(Dox) was measured at 0, 5, 10, 15, 20, 25, 30 day, and target PrP^C was added after 30 day. λ_{ex} , 490 nm; λ_{em} , 562 nm.